Three studies involving 3,092 patients with RA, PsA, or AS evaluated anti-TNFα drugs and reported an insignificant difference in the risk of tuberculosis following treatment with anti-TNFα agents. This evidence concerns the gene TNF and rheumatoid arthritis.